Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q1 FY27 results · Apr–Jun 2026
Gufic Biosciences reported revenue from operations of ₹260.82 crore (up 16.6% from Q1 FY26) and net profit of ₹22.31 crore (up 70.7% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 260.82 | 223.72 | +16.6% | 251.82 | +3.6% |
| Other income | 0.46 | 0.93 | −50.6% | (1.17) | Turned profit |
| Total income | 261.28 | 224.65 | +16.3% | 250.65 | +4.2% |
| Profit before tax | 30.04 | 17.27 | +73.9% | 28.95 | +3.8% |
| Net profit for the period | 22.31 | 13.07 | +70.7% | 21.90 | +1.9% |
| EPS, basic (₹) | 2.22 | 1.30 | +70.8% | 2.18 | +1.8% |
| Net margin (%) | 8.6 | 5.8 | 8.7 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 260.82 | 226.91 | +14.9% | 252.05 | +3.5% |
| Other income | 0.46 | 0.89 | −48.8% | (1.20) | Turned profit |
| Total income | 261.28 | 227.81 | +14.7% | 250.86 | +4.2% |
| Profit before tax | 30.16 | 16.28 | +85.3% | 27.63 | +9.2% |
| Net profit for the period | 22.46 | 12.07 | +86.0% | 20.57 | +9.2% |
| EPS, basic (₹) | 2.24 | 1.20 | +86.7% | 2.05 | +9.3% |
| Net margin (%) | 8.6 | 5.3 | 8.2 |
Consolidated
- Filed with BSE
- 14 Aug 2026, 20:03 IST
- Board meeting
- 14 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Aug 2026, 20:03 IST
- Board meeting
- 14 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE